Every material Form 8-K Xencor filed with the SEC in 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Xencor reported third quarter 2025 results on November 5, 2025, with revenue of $21.0 million, up from $17.8 million a year earlier, and a net loss of $6.0 million, or $(0.08) per share, compared with a net loss of $46.3 million, or $(0.72) per share, in the third quarter of 2024. The company said it expects to end 2025 with between $570 million and $590 million in cash, cash equivalents and marketable debt securities, and that it has cash to fund operations into 2028. Other income, net of $41.5 million, which was driven mainly by unrealized gains on marketable equity securities, helped narrow the loss.
Q3 2025 revenue was $21.0 million, versus $17.8 million in Q3 2024, primarily non-cash royalty revenue from Alexion and Incyte.
Q3 2025 net loss attributable to Xencor was $6.0 million, or $(0.08) per share, versus $46.3 million, or $(0.72) per share, a year earlier.
Research and development expenses fell to $54.4 million from $58.2 million, and general and administrative expenses were $14.2 million.
Cash, cash equivalents and marketable debt securities were $633.9 million as of September 30, 2025; year-end 2025 cash guidance is $570 million to $590 million.
Xencor reported second-quarter 2025 results, with revenue of $43.6 million, up from $23.9 million a year earlier, driven mainly by milestone revenue from Incyte. The net loss attributable to Xencor narrowed to $30.8 million, or $(0.41) per share, from $67.3 million, or $(1.09) per share, a year earlier, and the company expects to end 2025 with between $555 million and $585 million in cash and marketable debt securities.
Q2 2025 revenue was $43.6 million versus $23.9 million in Q2 2024, mainly milestone revenue from Incyte.
Q2 2025 net loss attributable to Xencor was $30.8 million, or $(0.41) per share, versus $67.3 million, or $(1.09) per share, in Q2 2024.
Cash, cash equivalents and marketable debt securities totaled $663.8 million as of June 30, 2025.
Xencor expects year-end 2025 cash of $555 million to $585 million and funding into 2028.
On July 31, 2025, Xencor appointed Raymond J. Deshaies, Ph.D., as a new member of its Board of Directors. He will receive an initial stock option grant with a Black Scholes value of $550,000 and a $50,000 annual cash retainer for board service.
Appointed to the board on July 31, 2025; he recently served as senior vice president of global research at Amgen Inc.
Initial option grant has a Black Scholes value of $550,000; one-third vests on the one-year anniversary, with the rest vesting in 24 monthly installments, fully vested at three years.
Receives a $50,000 annual cash retainer and is eligible for future equity compensation.
Xencor reported first-quarter 2025 revenue of $32.7 million, up from $16.0 million a year earlier, and a net loss attributable to Xencor of $48.4 million, or $(0.66) per share, compared with a $73.4 million loss, or $(1.20) per share, in the prior-year quarter. The company also said chief development officer Nancy Valente will leave that role effective June 6, 2025, and remain as a senior advisor.
Revenue was $32.7 million for the quarter ended March 31, 2025, versus $16.0 million a year earlier, mainly non-cash royalty revenue and milestone revenue from Incyte and Vir.
Net loss attributable to Xencor narrowed to $48.4 million, or $(0.66) per share, from $73.4 million, or $(1.20) per share.
R&D expenses rose to $58.6 million from $56.9 million, and G&A expenses rose to $17.3 million from $13.8 million.
Cash, cash equivalents and marketable debt securities totaled $693.5 million at March 31, 2025, versus $706.7 million at December 31, 2024; the company expects to end 2025 with $535 million to $585 million.
On March 13, 2025, Xencor appointed Todd Simpson, a former chief financial officer of Seagen Inc., as a new director and to the board's Audit Committee. The filing says his compensation includes an initial stock option grant with a Black Scholes value of $550,000 and annual cash retainers, which gives shareholders a clear view of the cost of the appointment.
Appointed to the Board of Directors and the Audit Committee on March 13, 2025
Initial nonstatutory stock option grant with an aggregate Black Scholes value of $550,000, vesting fully on the third anniversary of the grant date
Annual cash retainers of $50,000 for board service and an additional $10,000 for Audit Committee service
Served as CFO at Seagen for 18 years, through its acquisition in 2023
Xencor reported fourth-quarter and full-year 2024 results. Full-year revenue fell to $110.5 million from $174.6 million, and the net loss attributable to Xencor widened to $232.6 million, or $(3.58) per share, from $133.1 million, or $(2.20) per share. For shareholders, the filing also gives a 2025 year-end cash guidance range of $535 million to $585 million.
Q4 2024 revenue was $52.8 million, up from $51.0 million, driven mainly by Amgen and Novartis milestone revenue
Q4 2024 net loss attributable to Xencor was $45.6 million, or $(0.62) per share, versus $26.1 million, or $(0.43), a year earlier
Cash, cash equivalents and marketable debt securities were $706.7 million at December 31, 2024, up from $697.0 million
Company expects to end 2025 with between $535 million and $585 million in cash and marketable debt securities
Xencor's Audit Committee concluded on February 11, 2025 that its 2023 annual report and its three 2024 quarterly reports can no longer be relied upon. The errors involve accounting for a November 2023 royalty transaction with OMERS Life Sciences and the treatment of research and development and state tax items. The company identified material weaknesses in internal control over financial reporting and expects to file amended reports before its 2024 Form 10-K.
The royalty deal with OMERS Life Sciences should be treated as debt, not deferred income; deferred income was overstated by $156.9 million and debt understated by $168.5 million for 2023.
Cash flow from operating activities for 2023 was overstated by $163.0 million, with financing cash flow understated by the same amount; the filing says there is no impact on cash and marketable debt securities.
Tax errors add an uncertain tax position of $5.6 million for 2023 and state income tax expense understated by approximately $2.2 million, excluding interest and penalties.
RSM US LLP recalled its February 28, 2024 audit reports, and the company plans to file amendments to each prior filing.
Xencor said its preliminary, unaudited cash, cash equivalents and marketable debt securities were about $707 million at December 31, 2024, compared with $697.0 million a year earlier. The company expects this cash to fund research and development and operations into 2028, and the figures may change after year-end closing and audit procedures.
Preliminary, unaudited cash, cash equivalents and marketable debt securities of about $707 million at December 31, 2024, versus $697.0 million at December 31, 2023
Based on current operating plans, Xencor expects cash to fund research and development programs and operations into 2028
January 13, 2025 investor presentation also updated XmAb808 to resumed dose escalation and reported completed enrollment in three vudalimab studies
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Xencor filing is on SEC EDGAR ↗. 8-K briefs of other companies →